Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis (Protocol)

Kanie, T., Mizuno, A., Yoneoka, D., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O. and Kwong, J. S. (2020) Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis (Protocol). Cochrane Database of Systematic Reviews, 2020(6), CD013650. (doi: 10.1002/14651858.cd013650) (PMCID:PMC7387055)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To systematically review the available evidence on the effects (benefits and harms) of DPP‐4 inhibitors, GLP‐1 receptor agonists, and SGLT‐2 inhibitors in people with established CVD, using network meta‐analysis.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Wu, Professor Olivia
• Authors: Kanie, T., Mizuno, A., Yoneoka, D., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., and Kwong, J. S.
• College/School: College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
• Journal Name: Cochrane Database of Systematic Reviews
• Publisher: Wiley
• ISSN: 1469-493X
• Published Online: 24 June 2020
• Copyright Holders: Copyright © 2020 The Cochrane Collaboration
• First Published: First published in Cochrane Database of Systematic Reviews 2020(6): CD013650
• Publisher Policy: Reproduced in accordance with the publisher copyright policy